1-7 of 7
Zvenyslava Masliak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Free
Mohamad Mohty, MD PhD, Evangelos Terpos, Maria-Victoria Mateos, Antonio Palumbo, MD, Sandra Lejniece, Meral Beksac, MD, Mohamed Amine Bekadja, Wojciech Legiec, Meletios Dimopoulos, Svetlana Stankovic, PhD, Maria Soledad Durán, Valerio De Stefano, MD, Alessandro Corso, MD, Yulia Kochkareva, Edward Laane, MD PhD, Christian Berthou, MD PhD, Hans-Juergen Salwender, MD, Zvenyslava Masliak, Valdas Pečeliūnas, Wolfgang Willenbacher, MD, João Da Silva, Vernon Louw, Damir Nemet, MD PhD, Zita Borbényi, MD PhD, Uri Abadi, MD, Robert Schou Pedersen, Peter Cernelc, Anna Potamianou, MD PhD, Catherine Couturier, Robert Olie, PhD, Caroline Feys, MSc, MBA, Florence Thoret-Bauchet, Mario Boccadoro, MD
Journal: Blood
Blood (2015) 126 (23): 3034.
https://doi.org/10.1182/blood.V126.23.3034.3034
Published: 2015
Journal Articles

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Free
Johannes Drach, MD, Huiqiang Huang, MD, Olga S Samoilova, MD, Andrew Belch, MD, Charles M. Farber, MD PhD, André Bosly, MD PhD, Jan Novak, MD PhD, Jan Zaucha, MD PhD, Angela Dascalescu, MD PhD, Udomsak Bunworasate, MD, Zvenyslava Masliak, MD PhD, Kateryna Vilchevskaya, MD PhD, Tadeusz Robak, MD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD
Journal: Blood
Blood (2014) 124 (21): 3064.
https://doi.org/10.1182/blood.V124.21.3064.3064
Published: 2014
Journal Articles

Busulfan Exposure Decrease CCyR Rate On Imatinib Therapy - Impact On Recent Pretreatment

Free
Irina Dyagil, Elza Lomaia, Kudrat Abdulkadirov, Elena Goryunova, Natalia Lazorko, Ekaterina Romanova, Eugenia Sbityakova, Alla Abdulkadirova, Irina Martinkevich, Vera Udalieva, Elena Usacheva, Irina Zotova, Vasiliy Shuvaev, Elena Machulaitene, Ekaterina Poznyak, Maria Ivanova, Natalia Ilina, Elena Koryagina, Tatiana Shneider, Svetlana Stepanova, Irina Dmitrenko, Natalia Babkina, Tatiana Perekhrestenko, Zvenyslava Masliak, Andrey Zaritskey
Journal: Blood
Blood (2011) 118 (21): 4452.
https://doi.org/10.1182/blood.V118.21.4452.4452
Published: 2011
Journal Articles

High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival – Final Results of the CELSG Phase III CML11 “ISTAHIT” Trial

Free
Andreas L Petzer, Dominic Fong, Thomas Lion, Irina Dyagil, Zvenyslava Masliak, Andrija Bogdanovic, Laimonas Griskevicius, Sandra Lejniece, Stefan Goranov, Liana Gercheva, Aleksandar Stojanovic, Dontcho Peytchev, Nikolay Tzetkov, Rasa Griniute, Radka Oucheva, Thomas Grubinger, Marthin Kwakkelstein, Francesca Rancati, Günther A Gastl, Dominik Wolf
Journal: Blood
Blood (2010) 116 (21): 2271.
https://doi.org/10.1182/blood.V116.21.2271.2271
Published: 2010
Journal Articles

A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma

Free
Philippe Moreau, Halyna V Pylypenko, Sebastian Grosicki, Evgeniy E Karamanesht, Xavier Leleu, Maria E Grishunina, Grigoriy B Rekhtman, Zvenyslava Masliak, Tadeusz Robak, Anna V Shubina, Jean-Paul Fermand, Martin Kropff, James Cavet, Sudha Parasuraman, Huaibao Feng, Donna M Skee, Helgi van de Velde, William M Deraedt, Jean-Luc Harousseau
Journal: Blood
Blood (2010) 116 (21): 312.
https://doi.org/10.1182/blood.V116.21.312.312
Published: 2010
Journal Articles

CELSG CML 11 “ISTAHIT” Phase III Study – Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph + /BCR-ABL + CML Patients in Chronic Phase.

Free
Andreas L. Petzer, MD, Dominik Wolf, MD, Dominic Fong, MD, Thomas Lion, MD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Stefan Goranov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Radka Oucheva, MD, Hanno Ulmer, PhD, Marthin Kwakkelstein, MD, Gianluca Fincato, MD, Guenther Gastl, MD
Journal: Blood
Blood (2008) 112 (11): 1112.
https://doi.org/10.1182/blood.V112.11.1112.1112
Published: 2008
Journal Articles

Multicenter, Randomized, Phase III Study Comparing Imatinib (Glivec) Standard Dose (400 mg/d) with Imatinib High Dose Induction (800 mg/d) Followed by Imatinib Maintenance (400 mg/d) in Patients with Pretreated Ph + /BCR-ABL + CML in Chronic Phase - Results from the First Planned Interim Analysis (CELSG-CML 11 ISTAHIT Study).

Free
Andreas L. Petzer, MD, Dominik Wolf, MD, Dominik Fong, MD, Thomas Lion, MD, PhD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Emil Spasov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Atanas Stanchev, MD, Martin Kwakkelstein, MD, Hanno Ulmer, PhD, Guenther A. Gastl, MD
Journal: Blood
Blood (2007) 110 (11): 1048.
https://doi.org/10.1182/blood.V110.11.1048.1048
Published: 2007